Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Share

Enveda, an AI-driven biotech company, raised $311 million in funding at a $2 billion valuation to advance nature-derived drug candidates into clinical trials. The company is currently developing treatments for skin conditions and weight loss maintenance following GLP-1 therapy discontinuation.


Source: TechCrunch

Read more